Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.14
-0.0700-1.13%
Volume:595.54K
Turnover:3.65M
Market Cap:421.99M
PE:-2.64
High:6.31
Open:6.18
Low:6.00
Close:6.21
Loading ...

Collegium appoints Nancy Lurker to board of directors

TIPRANKS
·
05 Feb

Top Premarket Decliners

MT Newswires Live
·
05 Feb

EyePoint announces Phase 2 VERONA trial met primary endpoint

TIPRANKS
·
05 Feb

EyePoint Announces Positive Six-Month Results for the Phase 2 Verona Clinical Trial of Duravyu™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

THOMSON REUTERS
·
05 Feb

EyePoint Pharmaceuticals Inc - No Duravyu-Related Ocular or Systemic Saes Reported

THOMSON REUTERS
·
05 Feb

EyePoint Pharmaceuticals Inc - Primary Endpoint Achieved by Both Duravyu Doses

THOMSON REUTERS
·
05 Feb

EyePoint Pharmaceuticals Inc: Phase 3 Non-Inferiority Pivotal Program Initiation Anticipated by End of 2025 -

THOMSON REUTERS
·
05 Feb

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

GlobeNewswire
·
05 Feb

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

GlobeNewswire
·
30 Jan

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Jan

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
16 Jan

EyePoint Pharmaceuticals Inc: Cash Runway Into 2027 Beyond Topline Duravyu Phase 3 Wet Amd Data Expected in 2026

THOMSON REUTERS
·
13 Jan

EyePoint Pharmaceuticals: Full Data for Phase 2 Verona Clinical Trial of Duravyu in Dme Expected in 1Q 2025

THOMSON REUTERS
·
13 Jan

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

GlobeNewswire
·
13 Jan

Optimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular Edema

TIPRANKS
·
09 Jan

EyePoint Pharmaceuticals Strengthens Board with New Appointment

TIPRANKS
·
08 Jan